Invivo Therapeutics Holdings Corp Major Shareholder Francis Reynolds Unloads 24,000 Shares (NVIV)
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) major shareholder Francis Reynolds sold 24,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $1.72, for a total transaction of $41,280.00. Following the completion of the transaction, the insider now directly owns 11,487,920 shares in the company. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) in a research note to investors on Tuesday, August 27th. They now have a $2.00 price target on the stock. Analysts at Aegis raised their price target on shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) from $6.00 to $7.00 in a research note to investors on Friday, August 23rd. They now have a “buy” rating on the stock.
Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded down 10.83% on Wednesday, hitting $1.40. 1,267,408 shares of the company’s stock traded hands. Invivo Therapeutics Holdings Corp has a 52-week low of $0.94 and a 52-week high of $6.20. The stock has a 50-day moving average of $3.66 and a 200-day moving average of $3.35. The company’s market cap is $110.0 million.
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.